Cilian
Cilian AG is a German biotechnology company that develops and commercializes a novel protein expression platform based on ciliates, serving biopharmaceutical and industrial biotech manufacturers seeking an alternative to conventional recombinant production hosts.
- Company typePrivate
- Founded2001
- HeadquartersMünster, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
Cilian firmographics
Firmographics- Name
- Cilian
- Legal name
- Cilian AG
- Website
- https://cilian.de
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cilian AG is a German biotechnology company that develops and commercializes a novel protein expression platform based on ciliates, serving biopharmaceutical and industrial biotech manufacturers seeking an alternative to conventional recombinant production hosts.
- Ownership category
- akta.pro rank
Cilian industry classification
Industry- Product category
- Biotechnology / Protein Expression Services
- NAICS
- Chemical Manufacturing (325)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins) (AFAJAHAL)
Keywords
Where Cilian is headquartered
LocationHeadquarters
- HQ city
- Münster
- HQ country
- Germany
- HQ region
- Europe
Markets served
Cilian business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Cilian product offering
Product offeringCore offering
Cilian AG develops and markets a novel protein expression system based on ciliates, providing an alternative recombinant protein production platform for the biopharmaceutical industry. The company's core technology uses ciliate organisms as expression hosts for producing recombinant proteins intended for use in biopharmaceutical manufacturing and research applications.
Differentiator
Problem solved
Functional benefit
Companies that use Cilian
Customer profileIdeal customer profiles2 records
Cilian technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cilian competitors and assessment
Company assessmentDirect peers
- Lonza Group: Global biopharmaceutical CDMO and minority investor in Cilian. Comparable because Lonza operates the very protein expression and manufacturing services where Cilian's ciliate platform targets adoption.
- Cytiva: Supplies bioprocessing technologies, expression systems, and services for recombinant protein production. Highly comparable because Cytiva's portfolio directly addresses the same protein expression workflow Cilian's platform targets.
- Sartorius AG: Provides bioprocess equipment, filtration, and fermentation technologies used in recombinant protein manufacturing. Comparable because Sartorius serves the same downstream biomanufacturing customers evaluating alternative expression hosts.
- GenScript: Provides protein expression services and reagents across multiple host systems including mammalian, insect, and microbial. Comparable because GenScript competes in custom recombinant protein production that ciliate expression could address.
Broad incumbents
- Thermo Fisher Scientific (Gibco): Major life sciences incumbent offering protein expression reagents, cell lines, and CDMO services through its Gibco and Patheon brands. Comparable as a broad incumbent operating across expression systems and bioproduction.
- Merck KGaA (MilliporeSigma): Life science tools and bioprocessing supplier offering cell lines, expression media, and process services. Comparable as a broad incumbent providing components for the same recombinant protein workflows.
- Bio-Techne: Supplies proteins, reagents, and cell culture technologies used in research and bioprocess applications. Comparable as a broader incumbent whose protein and reagent catalog overlaps with the outputs of ciliate-based expression.
- Novonesis (formerly Novozymes): Industrial enzyme and microbial protein producer at very large scale. Comparable because Novonesis operates the large-scale alternative-host protein production that ciliate expression could potentially serve.
Emerging players
- ATUM (formerly DNA2.0): Synthetic biology company offering protein expression tools, gene synthesis, and proprietary expression platforms. Comparable as an emerging player developing alternative expression technologies for recombinant protein production.
- Phyton Biotech: Specializes in plant cell culture-based production of recombinant proteins and APIs. Comparable as an emerging player using non-mammalian eukaryotic expression hosts for complex protein production.
Market position
Customer concentration
Cilian social profiles
Digital presenceCilian financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cilian leadership team
Management profileNumber of profiles
Profiles3 records
Cilian funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cilian M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cilian
What does Cilian do?
Cilian AG develops and markets a novel protein expression system based on ciliates, providing an alternative recombinant protein production platform for the biopharmaceutical industry. The company's core technology uses ciliate organisms as expression hosts for producing recombinant proteins intended for use in biopharmaceutical manufacturing and research applications.
When was Cilian founded?
Cilian was founded in 2001. It employs 1 to 10 people.
Where is Cilian based?
Cilian is headquartered in Münster, Germany, in the Europe region.
Who are Cilian's main competitors?
Direct peers on record are Lonza Group, Cytiva, Sartorius AG and GenScript. Broad incumbents are Thermo Fisher Scientific (Gibco), Merck KGaA (MilliporeSigma), Bio-Techne and Novonesis (formerly Novozymes). Emerging players are ATUM (formerly DNA2.0) and Phyton Biotech.
Does Cilian have an API?
No public API is recorded for Cilian.
What industry is Cilian in?
Cilian's product category is Biotechnology / Protein Expression Services. Its primary akta.pro industry code is AFAJAHAL, Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins). Its NAICS code is 325 and its SIC code is 2833.